CO4970813A1 - Composicion farmaceutica bebible - Google Patents

Composicion farmaceutica bebible

Info

Publication number
CO4970813A1
CO4970813A1 CO98075012A CO98075012A CO4970813A1 CO 4970813 A1 CO4970813 A1 CO 4970813A1 CO 98075012 A CO98075012 A CO 98075012A CO 98075012 A CO98075012 A CO 98075012A CO 4970813 A1 CO4970813 A1 CO 4970813A1
Authority
CO
Colombia
Prior art keywords
amount
hydrochloride
pharmaceutical composition
equal
less
Prior art date
Application number
CO98075012A
Other languages
English (en)
Inventor
Claude Aleman
Philippe Bastard
Marielle Bonnel
Thierry Breul
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO4970813A1 publication Critical patent/CO4970813A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

Solución acuosa a base de clorhidrato de 1-[2-(2-naftil)etil]-4-(3-trifluorometilfenil)- 1,2,3,6- tetrahidropiridina (clorhidrato de SR 57746) caracterizada porque comprende: - una cantidad no nula de ß-CD inferior o igual a 50 mg/ml - una cantidad no nula de la cantidad de clorhidrato de SR 57746 (en mg/ml) inferior o igual al décimo de la cantidad de ß,-CD expresada en mg/ml; - un ácido o un tampón farmacéuticamente aceptables para asegurar un PH inferior o igual a 3; entendiéndose que para una cantidad de ß-CD que va de 30 a 50 mg/ml, la cantidad de clorhidrato de SR 57746 verifica la educación. Cantidad de clorhidrato de SR 577/mgml)
CO98075012A 1997-12-24 1998-12-17 Composicion farmaceutica bebible CO4970813A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9716529A FR2772614B1 (fr) 1997-12-24 1997-12-24 Solution aqueuse a base de chlorhydrate de 1- [ 2-(2-naphtyl)ethyl]-4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine et composition pharmaceutique buvable en contenant

Publications (1)

Publication Number Publication Date
CO4970813A1 true CO4970813A1 (es) 2000-11-07

Family

ID=9515152

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98075012A CO4970813A1 (es) 1997-12-24 1998-12-17 Composicion farmaceutica bebible

Country Status (25)

Country Link
US (1) US6191137B1 (es)
EP (1) EP1041984B1 (es)
JP (1) JP2002510599A (es)
AR (1) AR017722A1 (es)
AT (1) ATE252384T1 (es)
AU (1) AU1880599A (es)
BR (1) BR9814414A (es)
CA (1) CA2315696C (es)
CO (1) CO4970813A1 (es)
DE (1) DE69819203T2 (es)
DK (1) DK1041984T3 (es)
DZ (1) DZ2676A1 (es)
ES (1) ES2209238T3 (es)
FR (1) FR2772614B1 (es)
GT (1) GT199800204A (es)
HU (1) HUP0101012A3 (es)
MY (1) MY117156A (es)
NO (1) NO20003284L (es)
PT (1) PT1041984E (es)
SA (2) SA99191003B1 (es)
SI (1) SI1041984T1 (es)
TW (1) TW536409B (es)
UY (1) UY25320A1 (es)
WO (1) WO1999033466A1 (es)
ZA (1) ZA9811824B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087870A2 (en) * 2003-03-25 2004-10-14 The Johns Hopkins University Neuronal cell lineages and methods of production thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.

Also Published As

Publication number Publication date
AU1880599A (en) 1999-07-19
DE69819203D1 (de) 2003-11-27
FR2772614A1 (fr) 1999-06-25
DZ2676A1 (fr) 2004-09-19
CA2315696C (en) 2008-01-29
AR017722A1 (es) 2001-09-12
EP1041984B1 (fr) 2003-10-22
PT1041984E (pt) 2004-02-27
CA2315696A1 (en) 1999-07-08
SI1041984T1 (en) 2004-04-30
EP1041984A1 (fr) 2000-10-11
ES2209238T3 (es) 2004-06-16
FR2772614B1 (fr) 2000-03-10
DE69819203T2 (de) 2004-07-15
JP2002510599A (ja) 2002-04-09
MY117156A (en) 2004-05-31
NO20003284D0 (no) 2000-06-22
US6191137B1 (en) 2001-02-20
NO20003284L (no) 2000-08-24
BR9814414A (pt) 2000-10-10
DK1041984T3 (da) 2004-02-16
SA99191002B1 (ar) 2006-03-07
ATE252384T1 (de) 2003-11-15
GT199800204A (es) 2000-06-14
TW536409B (en) 2003-06-11
HUP0101012A2 (hu) 2001-08-28
WO1999033466A1 (fr) 1999-07-08
UY25320A1 (es) 2000-10-31
ZA9811824B (en) 1999-06-29
HUP0101012A3 (en) 2002-12-28
SA99191003B1 (ar) 2006-10-02

Similar Documents

Publication Publication Date Title
MX9505065A (es) Composicion farmaceutica, aplicable oralmente.
WO2000017190A3 (fr) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
MX9505064A (es) Composicion farmaceutica, aplicable oralmente.
BG103930A (en) Eletriptan hemisulphate and caffeine containing pharmaceutical compositions
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
PL346764A1 (en) New oral formulation for 5-ht4
UA41978C2 (uk) N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція
IL124091A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it
BR9811937A (pt) Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados
ATE245028T1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
CO4970813A1 (es) Composicion farmaceutica bebible
HK1045937A1 (en) Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof
ES2112555T3 (es) Composiciones farmaceuticas orales solubles en agua que contienen derivado de estrona y sales de calcio.
AU2382997A (en) Diclofenac/gamma-cyclodextrin inclusion compounds
MXPA03008837A (es) Una composicion farmaceutica estable de pravastatina.
TH43890A (th) สารดื่มทางเภสัชกรรม
CO5070670A1 (es) Taloproteinasas de arilsulfonamidas y estatinas
UA66776C2 (uk) Форма похідного тетрагідропіридину у вигляді мікрочастинок
MY152490A (en) New oral formulation
AU6404998A (en) Pharmaceutical composition for oral administration of heterocyclic compounds in the form of quaternary ammonium
BR0317067A (pt) Derivado cristalino de 2- (5-clorotien-2-il)-n-{ (3s)-1-[ (1s)-1-metil-2-morfolin-4-il-2-oxoetil] -2-oxopirrolidin-3-il) etenossulfonamida
ECSP982512A (es) Formulacion inyectable transparente de compuesto anestesico